报价延迟最少15分钟:2025/07/17 03:19 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.4 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.17/-1.50
|
|
企业价值
300.74M
|
| 资产负债 |
|
每股账面净值
2.22
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/17 03:19 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases. |
